Clinical efficacy of micafungin for chronic pulmonary aspergillosis

The rising incidence of pulmonary aspergillosis is a major clinical concern. However, only a limited number of antifungal drugs are available in Japan that are effective for pulmonary Aspergillus infections. Micafungin (MCFG), a newly developed echinocandin family antifungal drug, has potent antifun...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Medical mycology (Oxford) 2007-05, Vol.45 (3), p.273-278
Hauptverfasser:	Izumikawa, Koichi, Ohtsu, Yoshiko, Kawabata, Masateru, Takaya, Hisashi, Miyamoto, Atsushi, Sakamoto, Susumu, Kishi, Kazuma, Tsuboi, Eiyasu, Homma, Sakae, Yoshimura, Kunihiko
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Amphotericin B - therapeutic use Antifungal Agents - administration & dosage Antifungal Agents - adverse effects Antifungal Agents - therapeutic use Aspergillosis - diagnostic imaging Aspergillosis - drug therapy Aspergillosis - microbiology Aspergillus - drug effects Chronic Disease Drug Therapy, Combination Echinocandins Female Humans Itraconazole - therapeutic use Japan Lipopeptides Lipoproteins - administration & dosage Lipoproteins - adverse effects Lipoproteins - therapeutic use Lung Diseases, Fungal - diagnostic imaging Lung Diseases, Fungal - drug therapy Lung Diseases, Fungal - microbiology Male Middle Aged Peptides, Cyclic - administration & dosage Peptides, Cyclic - adverse effects Peptides, Cyclic - therapeutic use Radiography Retrospective Studies Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!